https://www.optimumcomms.com/wp-content/uploads/2023/12/Biocomposites_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-21 14:31:382025-10-24 16:27:46Biocomposites launches SYNICEM™ spacers in the U.S.
https://www.optimumcomms.com/wp-content/uploads/2023/12/Biocomposites_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-21 14:31:382025-10-24 16:27:46Biocomposites launches SYNICEM™ spacers in the U.S.
https://www.optimumcomms.com/wp-content/uploads/2023/08/Astraveus.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-21 08:34:142025-10-21 08:34:14Astraveus further strengthens world class leadership team to advance development of Lakhesys Benchtop Cell Factory™
https://www.optimumcomms.com/wp-content/uploads/2025/03/Novo_Holdings23_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-21 08:32:362025-10-21 08:32:36Novo Holdings co-leads €40m fundraising to scale MATR Foods’ production of organic plant-based meat alternatives
https://www.optimumcomms.com/wp-content/uploads/2025/10/Mission_Therapeutics_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-15 09:06:302025-10-15 09:06:30Mission Therapeutics raises $13.3 million to progress first-in-class Parkinson’s disease candidate MTX325 through clinical trials
https://www.optimumcomms.com/wp-content/uploads/2025/07/Actithera-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-14 08:32:542025-10-14 08:32:54Actithera Secures Exclusive Rights to Innovative Covalent Chemistry Technologies from Weizmann Institute for Targeted Radiopharmaceutical Applications
https://www.optimumcomms.com/wp-content/uploads/2025/01/Ona_Therapeutics_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-14 08:30:322025-10-14 08:33:36Ona Therapeutics Appoints Oncology Drug Development Veteran Dr. Antoine Yver as Chair to Accelerate ADC Programs to Clinical Inflection Points
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-10 09:12:332025-10-10 09:12:33Data from GNT-018-IDES trial supports feasibility of imlifidase as pretreatment in gene therapy treatment for patients with Crigler–Najjar syndrome who are immune to AAV
https://www.optimumcomms.com/wp-content/uploads/2024/03/Heidelberg_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-09 10:50:182025-10-10 10:24:10Heidelberg Pharma Reports on the First Nine Months of Financial Year 2025
https://www.optimumcomms.com/wp-content/uploads/2025/10/Glen-Clova_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-09 09:21:542025-10-09 15:06:52Glen Clova Scientific Announces Clinical Advisory Board for its Immuno-Dermatology Pipeline
https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-09 08:46:342025-10-09 08:47:15Resolution Therapeutics announces upcoming presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2025
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-08 17:15:302025-10-08 17:15:30Hansa Biopharma on 2nd October announced the raise of approximately USD 71 million through directed share issue
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-07 09:18:462025-10-07 09:18:46Optimum Strategic Communications to Host 17th Annual Healthcare Investor Conference
https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-07 08:36:052025-10-07 08:56:52Resolution Therapeutics to present EMERALD study design at the British Association for the Study of the Liver (BASL) annual meeting 2025
https://www.optimumcomms.com/wp-content/uploads/2023/02/Neuraxpharm_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-06 15:53:252025-10-06 15:53:25Neuraxpharm strengthens multiple sclerosis portfolio with the launch of Riulvy® (tegomil fumarate)
https://www.optimumcomms.com/wp-content/uploads/2025/10/Asabys_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-10-02 08:08:592025-10-02 08:53:39Asabys Partners Integrates Aliath Bioventures Life Sciences Investment Platform in Strategic Move with AltamarCAM
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-09-29 07:10:282025-09-29 07:10:28Poolbeg Pharma plc – Interim Results for the six months to 30 June 2025We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
